This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Developing E-liquid Product Standards (Sweet Spot Study) (NCT05864586), a randomized na study. The primary outcome is Behavioral Intentions for Continued Use.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05864586 |
| Phase | NA |
| Condition | Nicotine, Nicotine Vaping, E-cigarette Use |
| Allocation | Randomized |
| Design model | Factorial |
| Masking | Double |
| Enrollment | 150 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
| Results posted | Yes |
2. Clinical Question
Population
The study concerns young adult electronic-cigarette users with minimal or no history of smoking and older adult smokers. The record lists these as separate groups. It does not report the age limits used to define either group or further eligibility details.
Intervention
Participants took part in vaping sessions involving study e-cigarettes and e-liquids with nicotine varying in freebase level and concentration. The registry lists behavioral intervention entries named Vaping study EC A through Vaping study EC H. The relationship between these entries and the 10 study conditions described in the outcome timeframe is not reported in the registry record.
Comparator
The central comparison concerns appeal across the study conditions, including differences in nicotine form and concentration. The record does not specify a single reference product or a single pairwise comparator for the primary outcome. It describes assessments after each vaping session rather than one reduced comparison.
Primary question
After vaping a study product, how likely did participants say they were to continue using it? The primary outcome is a self-reported score on a scale from 1, extremely unlikely, to 7, extremely likely. Higher scores indicate greater stated likelihood of continued use. Numerical results for this outcome are not reported in the registry record.
3. Trial Design
The Sweet Spot Study is listed as a randomized, double-masked, factorial trial sponsored by the Ohio State University Comprehensive Cancer Center. Its status is completed, its phase is listed as NA, and its enrollment is 150. The registry lists a start date of 2023-05-30 and a primary completion date of 2024-02-26. These dates describe the trial record and do not establish when results were analyzed or posted.
The study focuses on the appeal of e-liquids with nicotine varying in freebase levels and concentrations. The described populations are young adult electronic-cigarette users with minimal or no smoking history and older adult smokers. The registry identifies eight behavioral intervention entries, labeled Vaping study EC A through Vaping study EC H. It does not describe the exact factor levels, the combinations assigned, or how the randomization was carried out.
The outcome timeframe says participants took two puffs of each of the 10 study conditions during each vaping session. Each session was assessed immediately afterward, within a single study visit lasting up to 3 hours. The relationship between the listed intervention entries and those conditions is not reported in the registry record. Details such as the order of exposure, washout procedures, and whether participants received every condition are also not reported.
Although the record labels masking as double, it does not identify which participants, staff, or other groups were masked, nor how masking was maintained. It also does not report the allocation ratio or the randomization unit. The factorial label indicates a design involving factors, but the protocol details needed to describe those factors or their planned contrasts are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Young Adult EC Users | Older Adult Smokers |
|---|---|---|
| STARTED | 70 | 80 |
| 20mg/mL Nicotine Concentration, 5% Free-base Fraction Study EC Device | 66 | 67 |
| 20mg/mL Nicotine Concentration, 25% Free-base Fraction Study EC Device | 66 | 66 |
| 20mg/mL Nicotine Concentration, 45% Free-base Fraction Study EC Device | 66 | 66 |
| 20mg/mL Nicotine Concentration, 65% Free-base Fraction Study EC Device | 66 | 66 |
| 20mg/mL Nicotine Concentration, 85% Free-base Fraction Study EC Device | 66 | 67 |
| 50mg/mL Nicotine Concentration, 5% Free-base Fraction Study EC Device | 66 | 66 |
| 50mg/mL Nicotine Concentration, 25% Free-base Fraction Study EC Device | 66 | 66 |
| 50mg/mL Nicotine Concentration, 45% Free-base Fraction Study EC Device | 66 | 66 |
| 50mg/mL Nicotine Concentration, 65% Free-base Fraction Study EC Device | 66 | 66 |
| 50mg/mL Nicotine Concentration, 85% Free-base Fraction Study EC Device | 66 | 66 |
| COMPLETED | 66 | 66 |
Reasons for not completing this period:
| Reason | Young Adult EC Users | Older Adult Smokers |
|---|---|---|
| Ineligible | 4 | 12 |
| Pregnancy | 0 | 1 |
| Withdrawal by Subject | 0 | 1 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Young Adult EC Users | Older Adult Smokers | Total |
|---|---|---|---|---|
| Participants analysed | 66 | 67 | 133 | |
| Age, Continuous | years | 22.12 (SD 1.16) | 39.39 (SD 6.71) | 30.82 (SD 9.91) |
| Sex: Female, Male: Female | Participants | 51 | 53 | 104 |
| Sex: Female, Male: Male | Participants | 15 | 14 | 29 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 3 | 1 | 4 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 3 | 9 | 12 |
| Race (NIH/OMB): White | Participants | 55 | 54 | 109 |
| Race (NIH/OMB): More than one race | Participants | 4 | 3 | 7 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 1 | 0 | 1 |
| Cigarettes Smoked per Day | cigarettes per day | 0.02 (SD 0.12) | 13.19 (SD 6.33) | 6.65 (SD 7.99) |
6. Primary Endpoint
The registry lists the primary outcome as Behavioral Intentions for Continued Use, measured over The outcome measure was assessed immediately after each vaping session. During each vaping session, participants took two puffs of each of the 10 study conditions within a single study visit lasting up to 3 hours..
| Element | Registry entry |
|---|---|
| Result type | Mean |
| Measure of spread | Standard Deviation |
| Unit | score on a scale |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is behavioral intentions for continued use, recorded as a mean score on a scale. Participants complete a self-report rating after e-cigarette self-administration. The rating ranges from 1, described as extremely unlikely to continue using the product, to 7, described as extremely likely. Higher scores indicate a higher stated likelihood of continued use.
The registry says the assessment occurs immediately after each vaping session. Participants take two puffs of each of the 10 study conditions during a session in a visit lasting up to 3 hours. This makes the endpoint a report of immediate, stated intention following product exposure, rather than a measure of later use or sustained behavior. Whether intentions correspond to later behavior is not reported in the registry record.
A mean summarizes the average score in a group or condition, while the standard deviation describes how spread out individual scores are around that average. These are useful summaries for a rating collected from many participants, but they do not by themselves show how different conditions compare or how precise a comparison is. The registry identifies the endpoint and its measurement scale, but does not report the mean scores, standard deviations, or an estimated contrast for the primary outcome.
Subjective appeal is listed as a secondary outcome. Its measurement details and numerical results are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The record describes a trial designed to examine whether nicotine form and concentration relate to product appeal in young adult electronic-cigarette users and older adult smokers. The primary endpoint is participants’ immediate self-reported likelihood of continuing to use the product after a vaping session. However, the registry record does not report numerical primary-outcome results. It therefore does not establish the direction or size of any observed difference between conditions or populations.
No primary-outcome means, standard deviations, confidence intervals, test statistics, or p-values are reported in the registry record. Without an estimated contrast and its uncertainty, readers cannot assess the magnitude or precision of a difference from the record. The completed status and enrollment figure describe the trial, but they are not evidence of a particular outcome.
The record lists four outcome measures and identifies subjective appeal as a secondary outcome. It also lists zero analyses. That distinction matters: an outcome can be registered without a numerical analysis being reported alongside it. The presence of a registered endpoint should not be mistaken for a posted estimate, and the absence of an analysis in the record does not establish that no analysis was conducted elsewhere.
The primary endpoint is measured after exposure to multiple study conditions. The record does not reduce these assessments to a single reported comparison, and it does not specify a primary contrast, a model for repeated measurements, or an adjustment strategy. Consequently, readers cannot determine from the registry how the investigators handled within-participant measurements, differences between the two listed populations, or the factorial structure when analyzing the endpoint.
The registry includes a sample-size planning illustration based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is described as a stated fraction of the observed effect. The resulting planning values are not reported in the registry record. In any case, such planning estimates are illustrations under assumptions, not observed power and not a substitute for the trial’s actual outcome estimates.
The reported safety counts are separate from the primary endpoint and do not answer the question about continued-use intentions. They describe adverse-event counts in the listed groups; they do not provide a comparative estimate of the primary outcome. Overall, the registry supports a description of the study question, design labels, endpoint, and selected safety counts, but not a conclusion about the observed primary-outcome pattern.
9. Statistical Methods Explained
The registry labels the study randomized, double-masked, and factorial. These design terms describe broad features, not a complete statistical analysis plan. The exact randomization procedure, masking roles, factor definitions, factor levels, and planned comparisons are not reported in the registry record. Without those details, the intended structure of the primary analysis cannot be reconstructed from the design labels alone.
What does a mean and standard deviation describe?
The endpoint is a score on a scale, and the record identifies the mean as the summary measure and the standard deviation as its dispersion measure. A mean represents the average score in the group or condition being summarized. A standard deviation describes how variable individual ratings are around that average. A mean is not a description of every participant’s response, and a standard deviation is not the uncertainty around a comparison between conditions.
As a general statistical explanation, an estimated difference between means describes the contrast in average scores for two specified conditions or groups. A confidence interval around that contrast communicates the range of values reasonably compatible with the data and the method used. A narrow interval generally reflects greater precision than a wide interval. The registry record does not report a contrast or confidence interval for the primary outcome, so these features cannot be assessed for this trial from the posted record.
Why does the factorial label matter?
In general, factorial designs examine more than one experimental factor, and can be used to evaluate factor-specific patterns as well as combinations of factor levels. The Sweet Spot Study description identifies nicotine freebase levels and concentrations as areas of interest, and labels the model factorial. The exact factors and levels, however, are not enumerated in the registry record. Nor does it specify whether the primary question concerns separate factor effects, interactions between factors, particular product contrasts, or another estimand.
The outcome timeframe describes repeated assessments after vaping study conditions. In general, measurements from the same participant may be related to one another, so an analysis may need to account for that dependence rather than treating every rating as independent. The record does not report the statistical model, covariance structure, handling of condition order, or treatment of repeated ratings. No particular approach should be inferred from the factorial label or the endpoint description.
What can significance testing and uncertainty tell readers?
As a general explanation, a p-value evaluates how compatible the observed data are with a specified null hypothesis under the assumptions of a statistical test. It is not the probability that the null hypothesis is true, and it does not measure the size or practical importance of an estimated effect. A confidence interval adds information about the estimate’s precision. Neither p-values nor confidence intervals for the primary endpoint are reported in the registry record.
When many outcomes, conditions, or contrasts are examined, the chance of obtaining a statistically unusual result by chance can increase across the collection of tests. A prespecified analysis plan and an approach to multiplicity can help readers understand how comparisons were chosen and interpreted. The registry lists four outcome measures but does not report a multiplicity strategy or a hierarchy of comparisons. It would therefore be inappropriate to assume that an adjustment was or was not used in an analysis outside the registry record.
How should the planning illustration be understood?
The registry describes a sample-size illustration using an observed effect, a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says the target effect is a stated fraction of the observed effect. Such calculations illustrate sample sizes under assumptions; they are not evidence of the study’s observed precision, and they are not observed power. The actual planning values and the fraction values are not reported in the registry record. The record also does not report the trial’s own sample-size justification, so the illustration should not be attributed to the original design protocol.
In general, power is a design-stage probability calculated for a specified effect, variability, test, and sample size under stated assumptions. It does not describe the probability that a completed trial’s finding is correct. A post hoc calculation based on an observed effect would not replace the estimate and its uncertainty. Since numerical endpoint results and their analysis are not reported in the registry record, readers cannot use this record to judge the observed effect’s precision.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists four outcome measures and names subjective appeal as a secondary outcome. It does not report how the primary outcome and secondary outcomes were ordered for confirmatory testing, which contrasts were prespecified, or whether any adjustment for multiple outcomes or comparisons was planned or applied. The endpoint timeframe covers multiple study conditions, but the registry does not identify a single primary contrast. Without this information, the intended control of multiplicity cannot be assessed.
Missing-data methods are not reported in the registry record. The record does not say whether every participant completed every condition, how incomplete ratings were handled, or whether any imputation or sensitivity analysis was used. It also does not report the number of participants contributing data to each endpoint assessment. Enrollment alone does not establish the analysis sample for a particular comparison.
Analysis populations are not described. The record does not specify whether analyses used all randomized participants, only participants with observed endpoint data, or another defined group. It also does not report exclusions or protocol-deviation rules. These details matter because the population included in an analysis can affect the meaning of an estimate.
The registry lists zero analyses, and numerical primary-outcome results are not reported in the registry record. This prevents assessment of the reported analytic choices and their consequences. It does not, by itself, establish what analyses may have been conducted outside the record.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Young Adult EC Users | 0 | 70 | 0.0% |
| Older Adult Smokers | 0 | 80 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Young Adult EC Users | 0 of 70 |
| Older Adult Smokers | 0 of 80 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Young Adult EC Users | 0 of 70 |
| Older Adult Smokers | 0 of 80 |
For young adult electronic-cigarette users, the registry lists 70 participants at risk for serious adverse events and zero serious adverse events; it also lists 70 at risk for other adverse events and zero other adverse events. For older adult smokers, it lists 80 at risk for serious adverse events and zero serious adverse events; it also lists 80 at risk for other adverse events and zero other adverse events. Deaths are listed as zero in both groups, and no top serious-event terms are listed.
These figures are counts in the registry’s adverse-event fields. They do not provide details about how events were defined, collected, or attributed, or the length of safety follow-up beyond what is stated for the vaping visit. Those details are not reported in the registry record. A count of zero means no event count is recorded for the specified category and group in this record; it does not establish that the chance of an event is zero, nor does it provide a comparison of risk between groups or products.
The adverse-event figures should also be kept distinct from the primary outcome. They do not indicate whether participants rated products as more or less appealing, and they do not substitute for numerical results on behavioral intentions for continued use.
12. What the Result Does, and Does Not, Mean
The registry record establishes that the Sweet Spot Study was completed, randomized, double-masked, and factorial, with enrollment of 150. It describes a study of nicotine form and concentration in e-liquids, and identifies young adult electronic-cigarette users with minimal or no smoking history and older adult smokers as the populations of interest. It also defines the primary endpoint as an immediate self-reported rating of likelihood of continued use after a vaping session.
Those design and measurement details do not reveal the outcome pattern. Numerical primary-outcome estimates, variability measures, and comparisons are not reported in the registry record. The direction, size, and precision of any differences among conditions or populations therefore cannot be determined from the record. The completed status does not fill that gap.
The primary endpoint measures stated intention immediately after product exposure. It is not, by definition, a measure of subsequent product use, persistence, or behavior outside the study visit. Whether the rating predicts later behavior is not reported in the registry record. The outcome description also does not establish how participants experienced conditions beyond the specific session described.
The record does not provide enough information to judge the primary analysis strategy, the handling of repeated ratings, missing observations, or multiplicity. It also does not identify a single comparison that can be interpreted as the definitive primary contrast. These gaps limit statistical interpretation, even though the endpoint and broad design are described.
Accordingly, the record can be used to understand what the investigators set out to measure and the broad populations and conditions involved. It cannot support a claim about which condition produced a higher or lower score, how large any difference was, or how certain an estimated difference would be. Those conclusions require outcome estimates and an analysis description that are not reported in the registry record.
13. Why This Trial Matters Statistically
This trial raises a statistical question that is more specific than whether participants generally find e-cigarettes appealing. It concerns self-reported intentions after exposure to products whose nicotine forms and concentrations vary, considered across two populations with different smoking histories. A factorial design can be useful for studying multiple product features, but interpreting it depends on knowing the factors, their levels, and the planned contrasts. The registry labels the design factorial without reporting those details.
The endpoint is collected immediately after each vaping session, and the timeframe describes ratings across multiple study conditions. Repeated measurements can offer information about within-participant patterns, but they also require careful analysis of dependence among observations. The analysis model and handling of repeated ratings are not reported in the registry record. This makes the analysis structure important to recognize rather than assume.
The study also illustrates the distinction between a registered outcome and a reported result. The primary outcome is clearly named and defined, yet numerical estimates and analyses are not reported in the registry record. Without those results, readers cannot evaluate effect size, precision, or the pattern across conditions. The trial design can be described, but its primary statistical findings cannot be characterized from this record.
Finally, the listed sample-size illustration should be read as planning context, not as evidence about the completed trial’s observed power or precision. It is based on stated assumptions and an observed effect, while the registry does not provide the resulting planning values or a trial-specific sample-size justification. Separating planning assumptions, design features, and outcome evidence is essential when interpreting clinical research records.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main trial-specific limitation for interpretation is the absence of numerical primary-outcome results in the registry record. The record defines behavioral intentions for continued use and describes when participants rated it, but does not report means, standard deviations, contrasts, confidence intervals, or test results. As a result, no quantitative conclusion about differences among conditions or populations can be drawn from this record.
The description covers multiple study conditions but does not state a single primary contrast. Although the design is labeled factorial and the study objective concerns freebase levels and nicotine concentrations, factor levels and the planned analysis of those factors are not reported in the registry record. The listed intervention entries run from EC A through EC H, while the outcome timeframe refers to 10 study conditions; the relationship between these descriptions is not stated.
Other details needed to evaluate the analysis are also absent, including the precise masking procedure, randomization method, analysis populations, handling of repeated measures, missing-data approach, and multiplicity strategy. The age limits and more detailed eligibility criteria for the two populations are not reported. These omissions restrict assessment of how the design was implemented and how representative the analyzed participants were.
The endpoint reflects immediate self-reported intentions after vaping. The record does not report whether ratings corresponded to later behavior, and the visit description does not establish longer-term outcomes. Safety counts are listed, but further event-collection and follow-up details are not reported in the registry record. These limitations do not negate the study’s stated question; they define what can and cannot be interpreted from the available registry information.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Developing E-liquid Product Standards (Sweet Spot Study) — NCT05864586.
- Registry record last updated 2025-04-10; status last verified 2025-03.
- Results first posted 2025-04-10.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The Sweet Spot Study is a completed, randomized, double-masked, factorial behavioral trial sponsored by the Ohio State University Comprehensive Cancer Center. The registry lists enrollment of 150 and identifies young adult electronic-cigarette users with minimal or no history of smoking and older adult smokers as the populations of interest. Its objective concerns appeal of e-liquids with varying nicotine freebase levels and concentrations.
The primary endpoint is a self-reported rating of likelihood of continued use, assessed immediately after vaping sessions. The timeframe describes two puffs of each of the 10 study conditions during a visit lasting up to 3 hours. Subjective appeal is listed as a secondary outcome. The registry lists zero analyses and does not report numerical primary-outcome results, so effect size and precision cannot be assessed from this record.
Adverse-event counts are listed as zero for serious events, other events, and deaths in both participant groups. Further analytic, missing-data, and safety-ascertainment details are not reported in the registry record.